Kallyope

Executive Summary

Kallyope is a private biotechnology company headquartered in New York City, founded in 2015. The company leverages unique insights into neural signaling pathways, particularly the gut-brain axis, to develop novel small molecule therapeutics for major health challenges. With a current focus on migraine and metabolic disorders, Kallyope is advancing a late-stage pipeline based on novel neural circuits. The company's platform integrates advanced neuroscience and computational biology to identify and target previously unexplored neural pathways, aiming to provide differentiated treatment options for patients with high unmet medical needs. Despite a relatively lean public profile, Kallyope has attracted interest for its innovative approach to modulating neural circuits implicated in disease.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 clinical data readout for lead migraine candidate60% success
• TBDSeries D financing announcement75% success
• Q3 2026Initiation of Phase 1 trial for metabolic disorder candidate70% success